PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290856
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290856
Antibody Discovery Services and Platforms Market size was valued at USD 4,008.7 million in 2022, expanding at a CAGR of 10.3% from 2023 to 2030.
Antibody discovery services and platforms are specialized tools and approaches used to identify and develop antibodies for various applications, such as therapeutics, diagnostics, and research tools. antibody discovery service platform uses industry-leading technologies and best-in-class humanized mice to discover high-quality antibodies for the target. Creative Biolabs has proudly developed the unique Native Antibody Discovery Platform to develop native monoclonal antibodies using antigen-specific B lymphocyte cytometry technology.
Increasing prevalence of infectious and chronic diseases and growth in awareness among individuals regarding early diagnosis detection, and personalized medicine are expected to propel the market growth.
Antibody discovery services and platforms play a crucial role in generating antibodies that can be used for diagnostic tests, therapeutics, and vaccine development. The demand for specific and sensitive antibodies to detect and combat these diseases fuels the growth of the market. According to the national health council, generally incurable and ongoing, chronic diseases affect approximately 133 million Americans, representing more than 40% of the total population of this country.2 By 2020, that number is projected to grow to an estimated 157 million, with 81 million having multiple conditions. Antibody discovery services and platforms provide a means to develop highly specific antibodies that can aid in early disease diagnosis. This demand for accurate and reliable diagnostic tools drives market growth. Overall, the Increasing prevalence of infectious and chronic diseases and growth in awareness among individuals regarding early diagnosis detection, and personalized medicine are expected to propel the Antibody Discovery Services and Platforms market growth.
The Global Antibody Discovery Services and Platforms Market is segmented on the basis of Process, nature, Method and Region.
The market is divided into five categories based on Process: Antigen Designing, Hit Generation, Lead Selection, Lead Optimization, and Lead Characterization. The process of antibody discovery typically involves several steps, which can be supported by various platforms and technologies.
The market is divided into two categories based on nature: Humanized, Human, Chimeric, and Murine. Humanized dominates the market. Antibody discovery services and platforms also offer humanization services as a part of the antibody development process.
The market is divided into two categories based on Method: Phage Display, Hybridoma, Transgenic Animal, Yeast Display and Single Cell. Phage Display dominates the market and is likely to maintain its dominance during the forecast period. Phage display is a powerful platform used in antibody discovery services for the identification and selection of antibodies with high affinity and specificity.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the Antibody Discovery Services and Platforms market, due to rising research and development spending on antibody discovery and a rise in demand for more efficient and effective treatment for a variety of diseases. According to estimates from the Business Research and Development Survey (BRDS), R&D with these health-related purposes represented 26% of the total USD 441 billion of R&D performed by businesses in the United States in 2018. Europe and Asia Pacific are projected to demand for Antibody Discovery Services and Platforms Market, due to the prevalence of infectious and chronic diseases.
Companies that develop innovative technologies for antibody discovery and optimization have a competitive edge. The antibody discovery services market has seen the emergence of several startups focusing on novel approaches and technologies. These companies often aim to disrupt the market with innovative platforms and methods. Manufactures are focusing on technological advancements, the ability to generate high-quality antibodies with desirable properties, portfolio of services, customer relationships, pricing strategies, regulatory compliance, and intellectual property portfolios. For example, Abzena, a leading CDMO providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a significant upgrade to its research and development capabilities in Cambridge. This includes investment in B cell discovery technologies and the appointment of Jamie Campbell as Vice President of Research & Development.
In May 2023, Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of integrated solutions from Idea to IND (I to ITM), nowadays announced it has entered into an agreement with ModeX Therapeutics, an OPKO Health company, for the use of Nona's platforms to support ModeX's development of multispecific antibody therapeutics.
The scope of this report covers the market by its major segments, which include as follows: